André Gundersen Deslauriers
Research Subjects
André Gundersen Deslauriers has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Eirini P. Papapetrou
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 shared publications - Ann-Charlotte Björklund
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
2 shared publications - Elli Papaemmanuil
Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications - Eva Hellström-Lindberg
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden
2 shared publications - Gabriele Todisco
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
2 shared publications - Indira Barbosa
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 26 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (11) , 2801-2811
SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms
Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS- SF3B1 ) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia. Precision medicine approaches for MDS- SF3B1 remain challenging due to both the complexity of the mis-splicing landscape and its evaluation in disease-accurate models. To uncover novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells and analyzed via unsupervised splicing event profiling using full-length RNA sequencing. This identified SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ), which encodes a key E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) introduced protein instability and decreased total UBA1 levels, rendering mutated cells susceptible to the small-molecule UBA1 inhibitor TAK-243. Analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, absent in other splicing factor-mutated MDS cases or healthy controls. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell numbers in colony-forming assays. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.
- 26 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (11) , 2801-2811
Open AccessSF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms
Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS- SF3B1 ) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia. Precision medicine approaches for MDS- SF3B1 remain challenging due to both the complexity of the mis-splicing landscape and its evaluation in disease-accurate models. To uncover novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells and analyzed via unsupervised splicing event profiling using full-length RNA sequencing. This identified SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ), which encodes a key E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) introduced protein instability and decreased total UBA1 levels, rendering mutated cells susceptible to the small-molecule UBA1 inhibitor TAK-243. Analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, absent in other splicing factor-mutated MDS cases or healthy controls. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell numbers in colony-forming assays. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.
- Open Access
SF3B1 -mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition
SF3B1 mutation-driven myelodysplastic syndromes (MDS- SF3B1 ) arise due to somatic mutation in the splicing factor SF3B1 gene. SF3B1 mutations induce RNA mis-splicing and loss of expression of critical genes for erythropoiesis, leading to erythroid dysplasia and ultimately refractory anemia. The development of precision medicine approaches for MDS- SF3B1 is hampered by the complexity of the mis-splicing landscape and its evaluation in disease-accurate model systems. To identify novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells in vitro and subjected to unsupervised splicing event analysis using full-length RNA sequencing data. This revealed SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ) transcripts, which encode the essential E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) preserved UBA1 ms mRNA but not protein expression. Consequently, UBA1 ms diminished the pool of functional UBA1, sensitizing SF3B1 K700E cell lines to the small-molecule UBA1 inhibitor TAK-243. Finally, analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, without detection in other splicing factor-mutated MDS patients, or in healthy individuals. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell number in colony-forming unit studies. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.
Open AccessSF3B1 -mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition
SF3B1 mutation-driven myelodysplastic syndromes (MDS- SF3B1 ) arise due to somatic mutation in the splicing factor SF3B1 gene. SF3B1 mutations induce RNA mis-splicing and loss of expression of critical genes for erythropoiesis, leading to erythroid dysplasia and ultimately refractory anemia. The development of precision medicine approaches for MDS- SF3B1 is hampered by the complexity of the mis-splicing landscape and its evaluation in disease-accurate model systems. To identify novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells in vitro and subjected to unsupervised splicing event analysis using full-length RNA sequencing data. This revealed SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ) transcripts, which encode the essential E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) preserved UBA1 ms mRNA but not protein expression. Consequently, UBA1 ms diminished the pool of functional UBA1, sensitizing SF3B1 K700E cell lines to the small-molecule UBA1 inhibitor TAK-243. Finally, analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, without detection in other splicing factor-mutated MDS patients, or in healthy individuals. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell number in colony-forming unit studies. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.
- Open Access
- 16 May 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (10) , 2992-3005
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E- and SF3B1WT-induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA and ATAC sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells. The chromatin landscape of SF3B1K700E HSPCs showed increased priming toward the megakaryocyte- erythroid lineage. Transcription factor motifs enriched in chromatin regions more accessible in SF3B1K700E cells included, unexpectedly, motifs of the TEA domain (TEAD) transcription factor family. TEAD expression and transcriptional activity were upregulated in SF3B1-mutant iPSC-HSPCs, in support of a Hippo pathway-independent role of TEAD as a potential novel transcriptional regulator of SF3B1K700E cells. This study provides a comprehensive characterization of the transcriptional and chromatin landscape of SF3B1K700E HSPCs and nominates novel mis-spliced genes and transcriptional programs with putative roles in MDS-RS disease biology.
- 16 May 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (10) , 2992-3005
Open AccessPatient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E- and SF3B1WT-induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA and ATAC sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells. The chromatin landscape of SF3B1K700E HSPCs showed increased priming toward the megakaryocyte- erythroid lineage. Transcription factor motifs enriched in chromatin regions more accessible in SF3B1K700E cells included, unexpectedly, motifs of the TEA domain (TEAD) transcription factor family. TEAD expression and transcriptional activity were upregulated in SF3B1-mutant iPSC-HSPCs, in support of a Hippo pathway-independent role of TEAD as a potential novel transcriptional regulator of SF3B1K700E cells. This study provides a comprehensive characterization of the transcriptional and chromatin landscape of SF3B1K700E HSPCs and nominates novel mis-spliced genes and transcriptional programs with putative roles in MDS-RS disease biology.
- Open Access
- 1 June 2020
- Published by Elsevier in Cell Reports
- Vol. 31 (9) , 107688
Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells
- 1 June 2020
- Published by Elsevier in Cell Reports
- Vol. 31 (9) , 107688
Open AccessAcute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells
- 9 July 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (13) , 1628-1632
Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin
Key Points: EMCN is a novel marker of human HSCs. EMCN is a more specific marker of HSCs than CD34 as it can discriminate HSCs from lineage-committed HPCs.
- 9 July 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (13) , 1628-1632
Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin
Key Points: EMCN is a novel marker of human HSCs. EMCN is a more specific marker of HSCs than CD34 as it can discriminate HSCs from lineage-committed HPCs.